AXSM
Price:
$93.185
Market Cap:
$4.47B
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective an...[Read more]
Industry
Biotechnology
IPO Date
2015-11-19
Stock Exchange
NASDAQ
Ticker
AXSM
According to Axsome Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -14.16. This represents a change of 17.33% compared to the average of -12.07 of the last 4 quarters.
The mean historical PE Ratio of Axsome Therapeutics, Inc. over the last ten years is -16.13. The current -14.16 PE Ratio has changed 8.68% with respect to the historical average. Over the past ten years (40 quarters), AXSM's PE Ratio was at its highest in in the December 2018 quarter at -2.19. The PE Ratio was at its lowest in in the September 2014 quarter at -109.79.
Average
-16.13
Median
-12.82
Minimum
-50.46
Maximum
-2.45
Discovering the peaks and valleys of Axsome Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.96%
Maximum Annual PE Ratio = -2.45
Minimum Annual Increase = -63.89%
Minimum Annual PE Ratio = -50.46
Year | PE Ratio | Change |
---|---|---|
2023 | -15.11 | -4.69% |
2022 | -15.86 | 50.55% |
2021 | -10.53 | -63.38% |
2020 | -28.76 | -43.00% |
2019 | -50.46 | 1.96% |
2018 | -2.45 | -44.41% |
2017 | -4.40 | -7.32% |
2016 | -4.75 | -54.68% |
2015 | -10.49 | -43.39% |
2014 | -18.52 | -63.89% |
The current PE Ratio of Axsome Therapeutics, Inc. (AXSM) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-13.83
5-year avg
-24.14
10-year avg
-16.13
Axsome Therapeutics, Inc.’s PE Ratio is less than Incyte Corporation (137.37), greater than ImmunoGen, Inc. (-122.93), less than Sarepta Therapeutics, Inc. (257.91), less than ACADIA Pharmaceuticals Inc. (87.04), greater than Viking Therapeutics, Inc. (-61.76), less than Madrigal Pharmaceuticals, Inc. (-10.23), less than Seres Therapeutics, Inc. (-0.89), less than Intercept Pharmaceuticals, Inc. (-13.55), less than TG Therapeutics, Inc. (33.32), less than Terns Pharmaceuticals, Inc. (-6.06), less than Hepion Pharmaceuticals, Inc. (-0.15), less than Akero Therapeutics, Inc. (-8.95), greater than Reata Pharmaceuticals, Inc. (-89.36), less than Day One Biopharmaceuticals, Inc. (-7.39), greater than Blueprint Medicines Corporation (-26.44), less than PDS Biotechnology Corporation (-2.64), less than Amylyx Pharmaceuticals, Inc. (-0.97),
Company | PE Ratio | Market cap |
---|---|---|
137.37 | $11.80B | |
-122.93 | $8.73B | |
257.91 | $12.29B | |
87.04 | $2.67B | |
-61.76 | $6.00B | |
-10.23 | $5.30B | |
-0.89 | $145.36M | |
-13.55 | $794.69M | |
33.32 | $3.41B | |
-6.06 | $549.60M | |
-0.15 | $4.20M | |
-8.95 | $1.83B | |
-89.36 | $6.57B | |
-7.39 | $1.25B | |
-26.44 | $5.47B | |
-2.64 | $107.88M | |
-0.97 | $161.36M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Axsome Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Axsome Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Axsome Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Axsome Therapeutics, Inc. (AXSM)?
What is the highest PE Ratio for Axsome Therapeutics, Inc. (AXSM)?
What is the 3-year average PE Ratio for Axsome Therapeutics, Inc. (AXSM)?
What is the 5-year average PE Ratio for Axsome Therapeutics, Inc. (AXSM)?
How does the current PE Ratio for Axsome Therapeutics, Inc. (AXSM) compare to its historical average?